↓ Skip to main content

Metoprolol, a Β-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease

Overview of attention for article published in Heart and Vessels, September 2003
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
33 Dimensions

Readers on

mendeley
20 Mendeley
Title
Metoprolol, a Β-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease
Published in
Heart and Vessels, September 2003
DOI 10.1007/s00380-003-0706-z
Pubmed ID
Authors

Ahmet Çamsarı, Serpil Arıkan, Candan Avan, Deniz Kaya, Hasan Pekdemir, Dilek ÇiÇek, Ahmet Kıykım, Kerem Sezer, Necdet AkkuŞ, Mehmet Alkan, Sinan Aydogˇdu

Abstract

The coexistence of coronary artery disease (CAD) and chronic obstructive pulmonary disease (COPD) is frequent because of common etiological factors. Beta-blockers remain underutilized in patients with CAD who also have COPD. This study was performed to evaluate the safety of beta-1 selective blocker agents in CAD patients with COPD. Fifty patients (aged 57.3 +/- 10.1 years) were enrolled in this study; 27 patients received metoprolol CR (controlled release), and 23 received metoprolol (conventional). The patients were stratified according to the severity of COPD (21 severe, 21 moderate, and 8 mild), started on metoprolol CR or conventional metoprolol, and titrated up to the maximum tolerated dose. The clinical controls were done during the first week and then at the first and third month. Patients received a mean total daily dose of 92.5 +/- 18 mg of metoprolol CR or 189 +/- 36.7 mg of metoprolol. Seven patients could not receive the maximum dose. There was no significant decrease in forced expiratory volume in 1 s (FEV(1)) in either group (basal vs last FEV(1): 54.5% +/- 13.4% vs 54.3% +/- 13% in the metoprolol CR group and 49.6% +/- 14.5% vs 53.2% +/- 12.8% in the metoprolol group). No adverse event was experienced. Metoprolol, a beta-1 selective blocker, can be used safely at the maximum dose in CAD patients with COPD.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 25%
Researcher 5 25%
Student > Bachelor 2 10%
Student > Doctoral Student 1 5%
Student > Postgraduate 1 5%
Other 0 0%
Unknown 6 30%
Readers by discipline Count As %
Nursing and Health Professions 4 20%
Medicine and Dentistry 4 20%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Agricultural and Biological Sciences 1 5%
Mathematics 1 5%
Other 2 10%
Unknown 7 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2016.
All research outputs
#20,655,488
of 25,373,627 outputs
Outputs from Heart and Vessels
#456
of 725 outputs
Outputs of similar age
#51,183
of 53,939 outputs
Outputs of similar age from Heart and Vessels
#2
of 2 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 725 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 53,939 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 2nd percentile – i.e., 2% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.